Unfortunately, a xenograft model of Ewing’s sarcoma cannot duplicate the single-agent efficacy of PARP inhibitors (Ordonez et al., 2015; Smith et al., 2015). This evidence concerns the gene PARP1 and Ewing sarcoma.